

Company name Nevia Bio \* Website <https://www.nevia.bio/>\*

CEO name Inbal Zafir-Lavie

CATEGORY: Biotech/Pharma

#### SESSIONS

Liquid biopsy & Diagnostics: Getting closer to transforming early detection and disease management

**o Executive Summary / Investment Rational** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

75% of ovarian cancer patients are diagnosed at late stages, resulting in extremely poor survival rates. Many other women-related diseases suffer from poor prognosis and poor quality of life due to lack of adequate diagnostics.

Nevia bio is developing a machine learning based, liquid biopsy platform of early detection in women's health space, using an untapped biofluid- vaginal secretions. The Nevia platform is designed to decode data from women's secretions, and to gain insights about physiological conditions, presenting **promising clinical results** in its first indication: **ovarian cancer**.

**o Core Technology** What is the technology, its uniqueness, and its value proposition?

Neiva Bio is developing a platform which enables decoding data from secretions. The company has built a platform that uses machine learning and data analysis strategies, that enables the identification of patterns in biofluids that can guide medical decisions. First use case: early detection of ovarian cancer.

Nevia Bio's mission is to bring accessible and affordable technologies to women around the world.

**o Product Profile/Pipeline** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

The women's health market is a growing market. Each indication in the company's pipeline has potential of capturing \$B size market.

Nevia has completed proof of concept, analyzing hundreds of samples collected from women of various populations. The data is used for the development of an ovarian cancer test along with other indications in the company's pipeline.

Nevia has completed the Mayo Clinic MedTech accelerator, and is collaborating with leading academic and clinical centers in the USA.

Nevia Bio was recognized by Frost and Sullivan for technology innovation and continues to strive for innovation in women's health

**o Business Strategy** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Nevia bio is bringing tools for women around the world. Starting from bringing early detection capabilities to ovarian cancer, the company aims to collaborate with distributors and payors to enable accessibility of this simple to use test.

In the long run, the company will tap into additional indications and strategic collaboration leveraging the data and knowhow that are accumulating as the company's activities expand.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

Nevia Bio is backed by significant stakeholders, and is currently initiating a pivotal trial in the USA and Eu, which will be followed by preparation for regulatory approval and product launch.